NDC 55513-400 – Amjevita
Adalimumab 40 mg/.8mL · Injection · Subcutaneous
Product NDC55513-400
Product details
- Brand name
- Amjevita
- Generic name
- Adalimumab-atto
- Labeler
- Amgen, Inc
- Dosage form
- Injection
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761024
- Marketed since
- January 31, 2023
- Listing expires
- December 31, 2027
- Pharmacologic class
- Tumor Necrosis Factor Blocker
Active ingredients
- Adalimumab 40 mg/.8mL
Package NDC codes (3)
| Package NDC | Description | Since |
|---|---|---|
| 55513-400-01 | 1 SYRINGE in 1 CARTON (55513-400-01) / .8 mL in 1 SYRINGE | Jan 31, 2023 |
| 55513-400-02 | 2 SYRINGE in 1 CARTON (55513-400-02) / .8 mL in 1 SYRINGE | Jan 31, 2023 |
| 55513-400-91 | 1 SYRINGE in 1 CARTON (55513-400-91) / .8 mL in 1 SYRINGE | Jan 31, 2023 |
Other Amjevita products
- 72511-482 Adalimumab 40 mg/.4mL · Injection · Amgen USA Inc.
- 72511-481 Adalimumab 80 mg/.8mL · Injection · Amgen USA Inc.
- 72511-479 Adalimumab 40 mg/.4mL · Injection · Amgen USA Inc.
- 72511-400 Adalimumab 40 mg/.8mL · Injection · Amgen USA Inc.
- 72511-399 Adalimumab 20 mg/.2mL · Injection · Amgen USA Inc.
- 55513-410 Adalimumab 40 mg/.8mL · Injection · Amgen, Inc
- 55513-482 Adalimumab 40 mg/.4mL · Injection · Amgen, Inc
- 55513-481 Adalimumab 80 mg/.8mL · Injection · Amgen, Inc
- 55513-480 Adalimumab 80 mg/.8mL · Injection · Amgen, Inc
- 55513-479 Adalimumab 40 mg/.4mL · Injection · Amgen, Inc
- 55513-413 Adalimumab 10 mg/.2mL · Injection · Amgen, Inc
- 55513-411 Adalimumab 20 mg/.4mL · Injection · Amgen, Inc